Examining Curative Therapies and Risk-Sharing at ISPOR Europe 2019 in Copenhagen, Denmark

October 10, 2019

Xcenda's global HEOR experts join more than 5,000 attendees from around the world at ISPOR Europe 2019 in Copenhagen. This energizing conference offers opportunities to debate value in healthcare beyond cost-containment and short-term interventions – strategic perspectives, scientific validity and diverse global experiences. Meet us at booth #C2-022 to meet our international team and learn how we can help you navigate the changing global healthcare landscape.

Optimizing Outcomes for Our Partners

Join us in Copenhagen and learn how we can optimize your brand's access.

Contact us

2019 Presentation Highlights

TUESDAY, 5 November 2019 | 12:30 - 13:30 Central European Time

SYMPOSIUM: Can We Afford Curative Therapies Without Sharing Risks? Perspectives on HTA and Affordability in This New Innovation Era

Moderator:  Jay Jackson, PharmD, MPH, Sr. Vice President, Xcenda, Palm Harbor, Florida, USA

Panelists:

Thomas Mittendorf, PhD, Vice President, Xcenda GmbH, Hannover, Germany

Christian Hill, Chief Executive Officer, MAPBiopharm, Cambridge, United Kingdom

Stève Bénard, Managing Director, stève consultants, Rhône-Alpes, France

Paola Lanati, Managing Director, MA Provider, Milan, Italy 

Gene therapy, ATMPs (advanced therapy medicinal products), or personalized medicine—all these buzz words are now part of the day-to-day reality in our industry. With several recent regulatory approvals across the globe, discussion has ensued in earnest on how to assess their value and whether traditional reimbursement systems and health economic methods are fit-for-purpose to meet the unique challenges being encountered. These challenges center less on whether the innovations provide value, and more on affordability in our current short-term global financing systems. To date, manufacturers have proactively addressed these topics with payers in various markets through pay-for-performance arrangements, milestone payments over various durations, and other novel payment schemes. All these developments over the short- and mid-term will lead to significant changes in how health care systems assess innovations during Health Technology Assessment pathways. Further, they will impact how financing systems evolve, especially with respect to risk sharing on potential outcomes. This symposium aims to provide insights on how payers and manufacturers across a number of important markets are currently dealing with these challenges.

Podium and Poster Presentations

Podium Presentation | Wednesday, 6 November | 9:45 - 10:45

  • EVALUATION OF THE EVOLVING TREATMENT LANDSCAPE IN EARLY-STAGE/LOCALLY-ADVANCED NON-SMALL CELL LUNG CANCER (ES/LA-NSCLC): A FORWARD-LOOKING NETWORK META-ANALYSIS (NMA) FEASIBILITY STUDY
    Authors: Rizzo M, Pollack M, Ballew NG, Kulp W, Wissinger E

Poster Session I | Monday, 4 November | 10:30 - 14:00

  • INCREASE OF SALPINGECTOMIES IN GERMANY SINCE 2005
    Authors: Altevers J, Jacob C

  • THE RELEVANCE OF REAL WORLD EVIDENCE STUDIES IN THE GERMAN BENEFIT ASSESSMENT (AMNOG) PROCESS
    Authors: Borchert K, Loepmeier JF, Braun S, Jacob C

  • AMNOG BENEFIT ASSESSMENT IN GERMANY AND ITS IMPACT ON PRICE NEGOTIATIONS
    Authors: Claes AK, Sauer AK, Freese L, Löpmeier JF, Erwes KL, Kulp W

  • SURROGATE VALIDATION IN GERMAN AMNOG BENEFIT ASSESSMENTS
    Authors: Gingrich A, Baigger A, Scharrenbroich J, Erwes KL, Kulp W, Templin C

  • REFERENCE PRICE GROUPS (RPG) DEFINED FROM 2008 TO 2018 IN GERMANY - A DETAILED OVERVIEW AND DISCUSSION
    Authors: Kuchenbecker U, Konstanski M, Mittendorf T

  • STATUS QUO OF CLAIMS DATA ANALYSES IN THE GERMAN AMNOG HTA PROCESS – DID QUALITY IMPROVE?
    Authors: Seidel K, Borchert K, Jacob C, Braun S, Mittendorf T

Poster Session II | Monday, 4 November | 15:30 - 19:00

  • CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-TS): ARE ONGOING CLINICAL TRIALS DESIGNED TO MEET EVIDENCE NEEDS OF KEY EUROPEAN HEALTH TECHNOLOGY ASSESSMENT BODIES (HTABS)?
    Author: Agashe V, Watts-James J, Arvin-Berod C, Martel MJ

  • KEY FACTORS FOR THE CONSIDERATION OF QUALITY OF LIFE DATA IN AMNOG BENEFIT ASSESSMENTS
    Authors: Billig S, Baigger A, Claes AK, Freese L, Kulp W

  • APPLICATION STUDY OF THE EQ-5D-5L IN ONCOLOGY: LINKING SELF-REPORTED QUALITY OF LIFE OF PATIENTS WITH ADVANCED OR METASTATIC COLORECTAL CANCER TO CLINICAL DATA FROM A GERMAN TUMOR REGISTRY – RESULTS FROM A TOBIT REGRESSION
    Authors: Borchert K, Altevers J, Jacob C, Mittendorf T, Braun S

  • RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON PROSTATE CANCER: RESULTS, RATIONALE, AND TRENDS
    Authors: Campbell D, Gittings K, Kanaskar A, Riggs K, Meyer K

  • FAST CHANGING APPROPRIATE COMPARATORS IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MULTIPLE MYELOMA
    Authors: Italia N, Claes AK, Löpmeier JF, Kulp W

  • RECENT HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS ACROSS THE GLOBE: A FOCUS ON NON-SMALL CELL LUNG CANCER: RESULTS, RATIONALE, AND TRENDS
    Authors: Kanaskar A, Campbell D, Campbell C, Riggs K, Meyer K
  • PREFERENCE ELICITATION FOR CANCER TREATMENT IN EUROPE: A SYSTEMATIC LITERATURE REVIEW OF DISCRETE CHOICE EXPERIMENTS
    Authors: Krinke K-S, König C, Jacob C, Mittendorf T, Braun S

  • GERMAN BENEFIT ASSESSMENT IN THE FIELD OF ONCOLOGY: FACTORS INFLUENCING THE BENEFIT RATING IN ADDITION TO COMPLYING WITH THE APPROPRIATE COMPARATOR
    Authors: Ulrich S, Damen D, Templin C, Kulp W

  • A SYSTEMATIC LITERATURE REVIEW (SLR) TO SUPPORT NETWORK META-ANALYSES (NMA) IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA (LA/MUC) FOLLOWING PD-1/L1 INHIBITORS
    Authors: Wissinger E, Ballew N

Poster Session III | Tuesday, 5 November | 10:30 - 14:00

  • A COMPARISON OF EUROPEAN MEDICINES AGENCY (EMA) AND FOOD AND DRUG ADMINISTRATION (FDA) PATIENT-REPORTED OUTCOME (PRO) GUIDANCES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    Authors: Gittings K, Kang I, Gaiser A, Louie D

  • THE BURDEN OF SEVERE HYPOPARATHYROIDISM IN GERMANY - A CLAIMS DATABASE ANALYSIS
    Authors: Maas C, Meise D, Jacob C, Braun S

  • ADDED BENEFIT ASSESSMENT OF ATMPS IN GERMANY: DOES THE DATA BASIS MEET HTA REQUIREMENTS?
    Authors: Templin C, Thamm K, Rinker F, Kulp W

Poster Session IV | Tuesday, 5 November | 15:45 - 19:00

  • PRICE ANALYSIS OF NEW MEDICINAL PRODUCTS REIMBURSED IN ITALY AND GERMANY
    Authors: Konstanski M, Kuchenbecker U, Mittendorf T

Poster Session V | Wednesday, 6 November | 9:30 - 14:00

  • A COMPARISON OF EUROPEAN MEDICINES AGENCY (EMA) AND FOOD AND DRUG ADMINISTRATION (FDA) PATIENT-REPORTED OUTCOME (PRO) GUIDANCES FOR GASTROINTESTINAL (GI) DISORDERS 
    Authors: SGittings K, Gaiser A

  • BURDEN OF MULTIPLE SCLEROSIS IN GERMANY – A MATCHED COHORT STUDY USING A LARGE CLAIMS DATABASE
    Authors: König C, Altevers J, Maas C, Meise D, Braun S

  • DATA SOURCES USED TO DETERMINE THE TARGET POPULATION SIZE FOR ORPHAN DRUGS - A REVIEW OF GERMAN AMNOG BENEFIT ASSESSMENTS
    Authors: Schneider KM, Seidel K, Röhrkaste J, Braun S

25 Years: Driving innovation in value and access.

Meet us at ISPOR Europe 2019 in Copenhagen, Denmark!

For 25 years, we’ve been there to help you navigate the complexities of the market so you can demonstrate the value of your product, maximize patient access, and enhance your overall brand performance.
Connect with us in Copenhagen